| Description | This product is a human monoclonal antibody that reacts with IL6. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | Recombinant full length protein (Human). |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | DB; WB; ELISA; FC; IP; FuncS; IF; Neut |
| Application Notes | The antibody is recommended for detection of IL6 by WB, ELISA, FC, IP, FuncS, IF, Neut assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | IL6 |
| Alternative Name | IL6; interleukin 6; HGF; HSF; BSF2; IL-6; IFNB2; interleukin-6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; interferon, beta 2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor |
| Gene ID | 3569 |
| UniProt | B4DVM1 |
| Research Area | Immunology; Neuroscience |
Figure 1 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in ELISA
ELISA analysis of V3S-0622-YC4769 was performed by coating with human IL6 protein (His tag). Then blocked with BSA and incubated with V3S-0622-YC4769. The HRP-conjugated goat anti-IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 1 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in ELISA
Figure 2 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in WB
Western blot analysis of V3S-0622-YC4769 was performed by loading human IL6 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4769 and HRP goat anti-IgG (H+L) as a secondary antibody (1: 3000). Chemiluminescent detection was performed.
Figure 2 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in WB
Figure 3 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in DB
Dot Blot analysis of V3S-0622-YC4769 was performed by coating with human IL6 protein (His tag).
V3S-0622-YC4769 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-IgG (H+L) as a secondary antibody (1: 3000)
NC: Negative control, PC: Positive control
Figure 3 Anti-Human IL6 Monoclonal Antibody (V3S-0622-YC4769) in DB
